Lexicon Pharmaceuticals, Inc. (LXRX)
NASDAQ: LXRX · Real-Time Price · USD
1.430
+0.050 (3.62%)
At close: Nov 6, 2025, 4:00 PM EST
1.370
-0.060 (-4.20%)
After-hours: Nov 6, 2025, 7:52 PM EST
Lexicon Pharmaceuticals Employees
Lexicon Pharmaceuticals had 103 employees as of December 31, 2024. The number of employees decreased by 182 or -63.86% compared to the previous year.
Employees
103
Change (1Y)
-182
Growth (1Y)
-63.86%
Revenue / Employee
$688,000
Profits / Employee
-$665,796
Market Cap
519.66M
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 103 | -182 | -63.86% |
| Dec 31, 2023 | 285 | 150 | 111.11% |
| Dec 31, 2022 | 135 | 48 | 55.17% |
| Dec 31, 2021 | 87 | 9 | 11.54% |
| Dec 31, 2020 | 78 | -106 | -57.61% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| UnitedHealth Group | 400,000 |
| Johnson & Johnson | 138,100 |
| Thermo Fisher Scientific | 125,000 |
| Abbott Laboratories | 114,000 |
| AstraZeneca | 92,900 |
| Novo Nordisk | 77,349 |
| Novartis AG | 75,883 |
| Merck & Co. | 75,000 |
LXRX News
- 10 hours ago - Lexicon Pharmaceuticals, Inc. (LXRX) Q3 2025 Earnings Call Transcript - Seeking Alpha
- 16 hours ago - Lexicon Pharmaceuticals Reports Third Quarter 2025 Financial Results and Provides R&D Updates - GlobeNewsWire
- 2 days ago - Data Demonstrating Unique Benefits of Sotagliflozin in Diverse Patient Populations will be Presented at the Hypertrophic Cardiomyopathy Society and American Heart Association's Sessions 2025 in New Orleans - GlobeNewsWire
- 7 days ago - Lexicon Pharmaceuticals to Report Third Quarter 2025 Financial Results on November 6, 2025 - GlobeNewsWire
- 23 days ago - Lexicon Pharmaceuticals Presents Additional Pilavapadin Data in Diabetic Peripheral Neuropathic Pain at 19th Annual Pain Therapeutics Summit - GlobeNewsWire
- 4 weeks ago - Lexicon Pharmaceuticals Convenes Roundtable to Address Public Policy Gaps for People with Chronic Pain - GlobeNewsWire
- 6 weeks ago - Lexicon Pharmaceuticals Announces Update on Submission of Additional Data to U.S. FDA Supporting the Benefit-Risk Profile of Zynquista® in Type 1 Diabetes - GlobeNewsWire
- 7 weeks ago - Pilavapadin Provides Meaningful Pain Reduction in Adults with Diabetic Peripheral Neuropathic Pain (DPNP) in Data Presented at the European Association for the Study of Diabetes (EASD) and NEUROdiab Annual Meetings - GlobeNewsWire